Is Inovio’s 232% Surge the Real Story Behind Monday’s Rally?

U.S. equity markets opened firmly in the green Monday morning, but the session’s defining move had nothing to do with index levels — a clinical-stage biotech with a market cap measured in the tens of millions just delivered the sharpest opening surge seen in this market in months.

The broader indices opened in tight formation. The S&P 500 started at 7,613.87, up 0.45%. The Nasdaq Composite opened at 25,596.07, gaining 0.63%, building on Friday’s stabilization after its worst monthly performance since March 2025. The Dow Jones Industrial Average led the pack at the open, rising 0.78% to 52,173.40 — extending gains as the session progressed to trade above 52,330. The backdrop matters: October was a punishing month for equities, and Monday’s open looks like a market searching for a reason to move higher. It found several. As we noted in our earlier look at this morning’s manufacturing data, the ISM PMI print at 10:00 AM ET will determine whether this open has structural support or is running purely on sentiment.

What Dropped Oil and Who Benefits

The single broadest catalyst for Monday’s green open isn’t an earnings report — it’s a geopolitical development. Oil prices fell more than 6% after reports of active U.S.-Iran peace deal negotiations emerged over the weekend. That kind of energy deflation acts as a tax cut for the economy: lower input costs for manufacturers, lower transport costs for retailers, lower fuel costs for consumers. The commodity decline filtered quickly into equity positioning, with energy sector names under pressure but consumer discretionary, industrials, and transport-adjacent stocks finding buyers. For a market that spent October absorbing a sequence of macro headwinds, cheaper oil is unambiguously constructive in the near term. The caveat: if negotiations stall, the relief rally in risk assets stalls with them.

Opening Bell Standout — Inovio Pharmaceuticals (INO)

Inovio Pharmaceuticals opened at $1.99 Monday morning, up 231.67% from Friday’s close of $0.60, after the FDA granted accelerated approval to VOCERYQ (INO-3107) late Friday evening. VOCERYQ becomes the first plasmid DNA-based immunotherapy approved in the United States, targeting recurrent respiratory papillomatosis — a rare, HPV-driven condition affecting the respiratory tract with few effective treatment options. Inovio said shipments are expected within 60 days, with full commercial deployment planned for early 2027.

Premarket activity was equally striking. More than 52.2 million shares changed hands before 9:30 AM, with the stock trading between $2.00 and $2.04 in the pre-open session — a range that held relatively tight given the scale of the move. The intraday high reached $2.07 in the first 15 minutes. That level is now the key reference point for bulls: clean continuation above $2.07 signals institutional willingness to chase. Failure to reclaim it after any pullback is the first sign of distribution.

Data Visual

INO Intraday Price Range vs. Previous Close (November 2, 2026)

Shows how far Inovio’s opening price of $1.99 diverged from Friday’s $0.60 close and where the early session high of $2.07 was established.

Values in $

The approval also landed alongside a legal win: Inovio secured an $80.4 million court judgment against VGXI and GeneOne, removing a secondary overhang that had weighed on the stock. Combined, the regulatory and legal catalysts shifted the company’s risk profile materially in a single weekend.

Regeneron and Rocket: Earnings That Held Their Ground

Beyond INO, Monday’s open reflected the tail end of a strong earnings week for select large-caps. Regeneron Pharmaceuticals (REGN) traded higher after reporting Q3 revenue of $5.116 billion against a consensus estimate of $4.597 billion — a beat of more than half a billion dollars. Non-GAAP EPS came in at $20.07 versus the Street’s $16.33. Revenue grew 36% year over year; earnings grew 70%. Dupixent, EYLEA HD, and Libtayo collectively drove those numbers, and the company announced a new dividend. Guggenheim raised its price target to $1,100 from $1,030, while Bank of America lifted its target to $1,030 from $908. Wells Fargo moved to $925 but held its Equal Weight rating — a notable outlier from the otherwise bullish chorus.

Data Visual

Regeneron Q3 2026 Revenue and EPS vs. Analyst Consensus

Illustrates the magnitude of Regeneron’s Q3 beat across both revenue and earnings per share relative to Wall Street estimates.

Rocket Companies (RKT) added roughly 7.4% premarket after reporting Q3 revenue of $3.28 billion versus consensus $2.59 billion, with adjusted EBITDA margins of 29% — the company’s strongest profitability margin in nearly five years. The Q4 guidance range of $2.10–$2.30 billion came in below the $2.57 billion consensus, which explains why the stock isn’t gapping 15%. The market is paying for the beat but discounting the deceleration. That’s a rational trade for now, but it sets a difficult comparison hurdle heading into the next quarter.

What the Volume Is Telling Us

INO’s first-15-minute volume tells one story. The broader tape tells another. The Nasdaq’s 0.63% gain at the open, following a month in which the index fell 5.3%, suggests positioning is cautious rather than aggressive. Buyers are participating but not rushing. That’s consistent with a market still processing October’s damage — the Nasdaq’s worst monthly decline since March 2025 — rather than one that has fully reset. As we discussed earlier this morning in our VIX analysis, volatility signals remain elevated even as index futures climbed, and that tension hasn’t fully resolved at the open. The Dow’s outperformance relative to the Nasdaq at the open — 0.78% versus 0.63% — is consistent with rotation toward value and defensive names rather than a pure risk-on session. When oil drops 6% and the Dow leads, that’s energy deflation lifting cyclicals, not a technology-led momentum chase.

Levels That Will Define the First Hour

The ISM Manufacturing PMI print at 10:00 AM ET is the session’s first real test. A reading above 50 — signaling expansion — would validate the broad risk-on tone and likely push the S&P 500 toward 7,650. A miss would test whether today’s rally has legs beyond oil-price relief and earnings tailwinds. For individual names, INO’s $2.07 intraday high is the line in the sand for momentum continuation. REGN needs to hold the $927–$930 zone — near its previous close of $927.89 — to confirm that the post-earnings premium is being absorbed cleanly rather than faded. Rocket Companies at $12.80 at open will face resistance near $13.50 if the Q4 guidance shortfall gets more attention as the session progresses. The broader market’s ability to sustain gains past the ISM release will reveal whether today is a genuine recovery open or a gap that gets sold.

Monday’s open is constructive on multiple fronts — a genuine FDA catalyst in INO, outsized earnings beats from REGN and RKT, and oil-price relief giving the macro backdrop breathing room. The question the first hour will answer is which of those forces has the most staying power. A market that rallied on one binary event in a micro-cap biotech and a commodity price drop is a market still in search of a durable thesis. Watch the S&P 500 at 7,650, INO at $2.07, and the ISM number at 10:00 AM — those three data points will define whether today is the start of a November recovery or simply a Monday that looked better than it was.

Want our briefings first? Add PreMarket Daily as a preferred source on Google to see more of our coverage in Top Stories.